CALCIMEDICA APPOINTS ROBERT N. WILSON, FORMER J&J VICE CHAIRMAN AS CO-CHAIRMAN OF THE BOARD OF DIRECTORS AND ERIC W. ROBERTS AS VICE CHAIRMAN

/in

Former Johnson & Johnson Vice Chairman, Robert N. Wilson, joins CalciMedica as Co-Chairman  Board Member, Eric W. Roberts, named Vice Chairman and Chairman of the Strategic Transactions and Finance Committee of the Board LA JOLLA, Calif., June 2, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels […]

Read more

CALCIMEDICA ANNOUNCES POSITIVE TOPLINE DATA FROM INTERIM ANALYSIS OF TRIAL EVALUATING AUXORA™ IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA

/in

Link to Full Article Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone  LA JOLLA, Calif., May 28, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute […]

Read more

CALCIMEDICA RAISES $15 MILLION IN SERIES C FINANCING ROUND LED BY VALENCE LIFE SCIENCES

/in

Link to Full Article Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™  LA JOLLA, Calif., May 22, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced it has […]

Read more

CALCIMEDICA ANNOUNCES THAT FDA HAS STRONGLY RECOMMENDED MOVING TO A BLINDED PLACEBO-CONTROLLED TRIAL WITH AUXORA™ IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA

/in

LA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) regarding the Company’s ongoing study of Auxora™ (formerly called […]

Read more